Expression and functional activity of chemokine receptors in glatiramer acetate-specific T cells isolated from multiple sclerosis patient receiving the drug glatiramer acetate

Human Immunology

Volumn 72, Issue 2, 2011, Pages 124-134

  Høglund, Rune Alexander ^a   Hestvik, Anne Lise ^b   Holmøy, Trygve ^b   Maghazachi, Azzam A ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemokine receptors; Chemotaxis; Glatiramer acetate; Inflammation; Multiple sclerosis; Th2 cells

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLATIRAMER; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; RANTES;

ARTICLE; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CELL MIGRATION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CHEMOTAXIS; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; BLOOD; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELLS, CULTURED; CEREBROSPINAL FLUID; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; INFLAMMATION; IONOMYCIN; LYMPHOCYTE ACTIVATION; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RECEPTORS, CCR4; RECEPTORS, CCR5; RECEPTORS, CCR6; RECEPTORS, CXCR3; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE;

EID: 78651252492     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.10.016     Document Type: Article

References (33)

1. Hestvik A.L.K. The double-edged sward of autoimmunity: Lessons from multiple sclerosis. Toxins 2010, 2:856-877.
2. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009, 9:393-407.
3. Bruserud Ø., Kittang A.O. The chemokine system in experimental and clinical hematology. Curr Top Microbiol Immunol 2010, 341:3-12.
4. Bonecchi R., Savino B., Borroni E.M., Mantovani A., Locati M. Chemokine decoy receptors: Structure-function and biological properties. Curr Topics Microbiol Immunol 2010, 341:15-36.
5. Balashov K.E., Rottman J.B., Weiner H.L., Hancock W.W. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999, 96:6873-6878.
6. McManus C., Berman J.W., Brett F.M., Staunton H., Farrell M., Brosnan C.F. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: An immunohistochemical and in situ hybridization study. J Neuroimmunol 1998, 86:20-29.
7. Simpson J.E., Newcombe J., Cuzner M.L., Woodroofe M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998, 84:238-249.
8. Teleshova N., Pashenkov M., Huang Y.M., Söderström M., Kivisäkk P., Kostulas V., et al. Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid. J Neurol 2002, 249:723-729.
9. Reboldi A., Coisne C., Baumjohann D., Benvenuto F., Bottinelli D., Lira S., et al. C-C chemokine receptor 6-regulated entry of Th-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009, 10:514-523.
10. Aharoni R., Teitelbaum D., Sela M., Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 1998, 91:135-146.
11. Valenzuela R.M., Costello K., Chen M., Said A., Johnson K.P., Dhib-Jalbut S. Clinical response to glatiramer acetate correlates with modulation of IFN-γ and IL-4 expression in multiple sclerosis. Mult Scler 2007, 13:754-762.
12. Weber M.S., Hohlfeld R., Zamvil S.S. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007, 4:647-653.
13. Aharoni R., Kayhan B., Eilam R., Sela M., Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A 2003, 100:14157-14162.
14. Weber M.S., Starck M., Wagenpfeil S., Meinl E., Hohlfeld R., Farina C. Multiple sclerosis: Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004, 127:1370-1378.
15. Weber M.S., Prod'Homme T., Youssef S., Dunn S.E., Rundle C.D., Lee L., et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007, 13:935-943.
16. Al-Falahi Y., Sand K.L., Knudsen E., Damaj B.B., Maghazachi A.A. Splenic natural killer cell activity in two models of experimental neurodegenerative diseases. J Cell Mol Med 2009, 13:2693-2703.
17. Sand K.L., Knudsen E., Rolin J., Al-Falahi Y., Maghazachi A.A. Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol Life Sci 2009, 66:1446-1456.
18. Hestvik A.L.K., Skorstad G., Price D.A., Vartdal F., Holmoy T. Multiple sclerosis: Glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid. Mult Scler 2008, 14:749-758.
19. Jin Y., Knudsen E., Wang L., Bryceson Y., Damaj B., Gessani S., Maghazachi A.A. Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. Blood 2003, 101:4909-4915.
20. Inngjerdingen M., Damaj B., Maghazachi A.A. Expression and regulation of chemokine receptors in human natural killer. Cells. Blood 2001, 97:367-375.
21. Taub D.D. Neuroendocrine interactions in the immune system. Cell Immunol 2008, 252:1-10.
22. Maghazachi A.A. Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol 2010, 341:37-58.
23. Misu T., Onodera H., Fujihara K., Matsushima K., Yoshie O., Okita N., et al. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: Imbalance of Th1/Th2-associated chemokine signaling. J Neuroimmunol 2001, 114:207-212.
24. Kupper T.S., Fuhlbrigge R. Immune surveillance in the skin: Mechanisms and clinical consequences. Nat Rev Immunol 2004, 4:211-222.
25. Wang C., Kang S.G., Lee J., Sun Z., Kim C.H. The roles of CCR6 in migration of Th17 cells and regulation of effector cell balance in the gut. Mucosal Immunol 2009, 2:173-183.
26. Maghazachi A.A. G. Protein-coupled receptors in natural killer cells. J Leukoc Biol 2003, 74:16-24.
27. Maghazachi A.A. Insights into seven and single transmembrane spanning domain receptors and their signaling pathways in human natural killer cells. Pharmacol Rev 2005, 57:339-357.
28. Allie R., Hu L., Mullen K.M., Dhib-Jalbut S., Calabresi P.A. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch Neurol 2005, 62:889-894.
29. Luster A.D. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 2002, 14:129-135.
30. Martin R., Stürzebecher C.S., McFarland H.F. Immunotherapy of multiple sclerosis: Where are we? Where should we go?. Nat Immunol 2001, 2:785-788.
31. Boggild M. Immunosuppression followed by immunomodulation. J Neurol Sci 2009, 51:550-554.
32. Ramtahal J., Jacob A., Das K., Boggild M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 2006, 253:1160-1164.
33. Mackay I.R., Leskovesk N.V., Rose N.R. Cell damage and autoimmunity: A critical appraisal. J Autoimmun 2007, 30:5-11.